US 11,879,015 B2
Antibodies or antigen-binding fragments that bind to OX40
Xiang Li, Beijing (CN); Guoqian Sun, Beijing (CN); Chenguang Cai, Beijing (CN); Shiying Fu, Beijing (CN); Ting Yang, Beijing (CN); Shuang Zhao, Beijing (CN); Ying Li, Beijing (CN); Xinyue Dai, Beijing (CN); Qi Sun, Beijing (CN); Fengzhi Zhang, Beijing (CN); Youyou Lin, Beijing (CN); Yu Chen, Beijing (CN); Zhengfei Xue, Beijing (CN); Hui Pang, Beijing (CN); Ying Bai, Beijing (CN); and Shin-chen Hou, Beijing (CN)
Assigned to BIODURO (BEIJING) CO., LTD., Beijing (CN)
Filed by BIODURO (BEIJING) CO., LTD., Beijing (CN)
Filed on Apr. 29, 2022, as Appl. No. 17/661,436.
Claims priority of application No. 202110480042.X (CN), filed on Apr. 30, 2021.
Prior Publication US 2022/0348670 A1, Nov. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2866 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. A nanobody that binds to OX40, comprising:
a) a CDR1, a CDR2 and a CDR3 having the amino acid sequences as shown in SEQ ID NOs: 1, 2 and 3, respectively;
b) a CDR1, a CDR2 and a CDR3 having the amino acid sequences as shown in SEQ ID NOs: 4, 5 and 6, respectively;
c) a CDR1, a CDR2 and a CDR3 having the amino acid sequences as shown in SEQ ID NOs: 7, 8 and 9, respectively; or
d) a CDR1, a CDR2 and a CDR3 having the amino acid sequences as shown in SEQ ID NOs:
10, 11 and 12, respectively.